NXL105

NXL105 is a novel anti-Pseudomonal antibiotic that was in preclinical development by Novexel SA, a specialty pharmaceutical company focused on discovering and developing novel antibiotics to overcome bacterial resistance. The drug was designed to target serious Gram-negative bacterial infections, specifically those caused by *Pseudomonas aeruginosa*, which are commonly found in hospital settings. According to preclinical reports from 2008-2009, NXL105 was described as having a dual mechanism of action involving the inhibition of bacterial topoisomerases and cell wall synthesis. The compound was part of Novexel's pipeline of antibacterial agents targeting the global hospital antibiotic market. Development of NXL105 appears to have been discontinued following Novexel's acquisition by AstraZeneca in 2010, as no further clinical advancement has been documented.